Cannabinoid Regulation of Murine Vaginal Secretion

Biomolecules, Journal Year: 2025, Volume and Issue: 15(4), P. 472 - 472

Published: March 24, 2025

Tearing and salivation are wholly dependent on the activity of exocrine (lacrimal salivary) glands, whereas vaginal moisture secretion rely a combination exudation secretion. Exocrine gland disorders impact millions, women with Sjögren's Syndrome often experience dry eye mouth as well dryness. Cannabis users' complaints 'cottonmouth' well-known, but some female cannabis users also report The regulation by cannabinoid signaling system is essentially unstudied. We recently reported that despite their small size nocturnal nature, laboratory mice have measurable basal pheromone-stimulated secretory responses regulated circadian estrous factors. tested CB1 receptors in this model. now receptor agonist CP55940 does not alter baseline prevents stimulated response due to local peri-vaginal effect. Chronic intermittent reduces unmasks or induces potentiating effect for CP55940, suggesting multiple sites action. acute chronic effects likely occur via receptors. Δ9-tetrahydrocannabinol (THC), chief psychoactive ingredient cannabis, partial at CB1, has no effects. In summary, strong activation murine model reduce prevent response. contrast, moisture. extent which these findings translate humans remains be determined.

Language: Английский

---

A randomized, double-blind, placebo-controlled, repeated-dose pilot study of the safety, tolerability, and preliminary effects of a cannabidiol (CBD)- and cannabigerol (CBG)-based beverage powder to support recovery from delayed onset muscle soreness (DOMS)

Journal of the International Society of Sports Nutrition, Journal Year: 2023, Volume and Issue: 20(1)

Published: Nov. 10, 2023

Cannabinoid-containing products are marketed to athletes as promoting recovery, in spite of a lack data on their safety and effects. This randomized, double-blind, placebo-controlled, repeated-dose pilot study tested the safety, tolerability, preliminary effects recovery formulation containing cannabidiol (CBD; 35 mg), cannabigerol (CBG; 50 beta caryophyllene (BCP; 25 branched-chain amino acids (BCAAs; 3.8 g), magnesium citrate (420 mg).Exercise-trained individuals (N = 40) underwent an experimental induction delayed onset muscle soreness (DOMS) completed follow-up visits 24-, 48-, 72-hours post-DOMS. Participants were randomized active or placebo formulation, consumed twice per day for 3.5 days.There was one adverse event (AE) group (diarrhea) two AEs (dry mouth; eye rash/swollen eye). There 100% self-reported compliance with consumption across groups. For primary outcome interest, estimate effect ratings average soreness/discomfort 72 hours post-DOMS between groups -1.33 (85% confidence interval -2.55, -0.10), suggesting moderate evidence treatment difference. The interference soreness, discomfort, stiffness daily activities at work home 48 -1.82 (95% -3.64, -0.01), indicating difference potential clinical importance. no significant objective measures sleep quality, mood disturbance.The reduced DOMS activities, demonstrating its improvement functional aspect recovery.

Language: Английский

---

The Development of Cannabinoids as Therapeutic Agents in the United States

Pharmacological Reviews, Journal Year: 2024, Volume and Issue: 76(5), P. 915 - 955

Published: June 7, 2024

Cannabis is one of the oldest and widely used substances in world. Cannabinoids within cannabis plant, known as phytocannabinoids, mediate cannabis9 effects through interactions with body9s endogenous cannabinoid system. This system, endocannabinoid has important roles physical mental health. These point to potential develop cannabinoids therapeutic agents, while underscoring risks related interfering system during non-medical use. scoping narrative review synthesizes current evidence for both adverse major (i.e., Δ9-tetrahydrocannabinol cannabidiol) lesser studied minor from nonclinical clinical research. We pay particular attention areas where well-established, including analgesic after acute exposures neurocognitive chronic In addition, drug development considerations agents United States are reviewed. The proposed study design encourage methodological standards greater scientific rigor reproducibility, ultimately, extend our knowledge benefits patients providers. Significance Statement work provides a prior research context States. also provide future development.

Language: Английский

---

Effects of Cannabis on Glutamatergic Neurotransmission: The Interplay between Cannabinoids and Glutamate

Cells, Journal Year: 2024, Volume and Issue: 13(13), P. 1130 - 1130

Published: June 29, 2024

There has been a significant increase in the consumption of cannabis for both recreational and medicinal purposes recent years, its use can have long-term consequences on cognitive functions, including memory. Here, we review immediate effects derivatives glutamatergic neurotransmission, with focus presynaptic postsynaptic alterations. Several factors influence cannabinoid-mediated changes dosage, sex, age, frequency use. Acute exposure to typically inhibits glutamate release, whereas chronic tends release. Conversely, alterations are more complicated than effects, as affect receptor expression downstream signaling glutamate. All these ultimately particularly This will cover current research glutamate–cannabis interactions, well future directions needed understand cannabis-related health neurological psychological aspects

Language: Английский

---

Quantification of 7 cannabinoids in cannabis oil using GC-MS: Method development, validation and application to therapeutic preparations in Friuli Venezia Giulia region, Italy

Heliyon, Journal Year: 2023, Volume and Issue: 9(4), P. e15479 - e15479

Published: April 1, 2023

The use of therapeutic cannabis preparations in Friuli Venezia Giulia is increasingly expanding. Even if oil finds its applications several disorders affecting adults and children, it not yet a standardized product and, to ensure the quality preparation, quantitative analysis must be carried out before dispensing patients. Gas chromatography coupled mass spectrometry (GC-MS) frequently used technique for quantification cannabinoids, active compounds C. sativa. In this context, we developed GC-MS method simultaneous 7 cannabinoids (CBD, CBDA, CBG, CBN, THCA, THCV Δ9-THC) that time sample consuming: 10 μL were consists derivatization analytes through silylation. Calibration curves built from 0.2 2 μg/mL. percentage accuracy precision did exceed values recommended by validation guidelines. limit detection was 0.01 μg/mL; whereas lower There no carry over. proposed showed good sensitivity, specificity, linearity, accuracy, applicability preparations.

Language: Английский

---

Cannabidiol as a Harm Reduction Strategy for People Who Use Drugs: A Rapid Review

The Canadian Journal of Psychiatry, Journal Year: 2023, Volume and Issue: 68(8), P. 557 - 571

Published: June 27, 2023

Objective The drug poisoning crisis throughout North America necessitates novel harm reduction approaches. Emerging evidence suggests that cannabidiol (CBD) may have some utility as a modality for those with problematic substance use. This rapid review aimed to synthesize available on CBD potential tool people who use drugs while providing clinical and research insights. Method A systematic search in EMBASE, MEDLINE, CENTRAL, CINAHL was completed July 2022. For inclusion, studies had meet the following criteria: (1) drawn from an adult population of drugs; (2) investigates intervention or reduction–related outcomes; (3) be published after year 2000 English; (4) primary article. narrative synthesis used group outcomes relevant provide Results We screened 3,134 records, which 27 (5 randomized trials) were included. remains limited, but support reduce drug-induced craving anxiety opioid disorder. There low-quality suggesting improve mood general well-being drugs. Evidence monotherapy not adequate strategy rather adjunct standard care. Conclusion Low-quality cravings other addiction-related symptoms However, there is significant need more accurately reflects dosing administration regimens real-world context.

Language: Английский

---

A Survey Study of Individuals Using Hexahydrocannabinol Cannabis Products: Use Patterns and Perceived Effects

Cannabis and Cannabinoid Research, Journal Year: 2023, Volume and Issue: 9(5), P. e1385 - e1394

Published: Nov. 7, 2023

Introduction: Across the cannabis market, multiple cannabinoids have seen rapid growth. Considering differing effects between specific cannabinoids, it is critical to assess on an individual level. Hexahydrocannabinol (HHC) one intoxicating cannabinoid that became more accessible due regulatory shifts. The purpose of current study was provide descriptive data regarding HHC use patterns and perceived within a sample participants who endorsed recent use. Methods: One hundred nine individuals self-reported HHC-cannabis product at least once 6 months completed questionnaire via Prolific, online crowdsourcing platform. Results: Findings suggest users are using relatively frequently (∼10 days during past month) for various indications, including anxiety pain. yield good than bad effects, relaxation euphoria. Approximately 17% reported adverse ∼20% those stopped experienced some withdrawal symptoms. Few meaningful sex differences in subjective effect ratings were observed. Discussion: provides preliminary about consumer related HHC. Such needed further research potential therapeutic as well detrimental better inform consumers, health professionals, regulators widely available market.

Language: Английский

---

Impact of Dietary Fat and Oral Delivery System on Cannabigerol Pharmacokinetics in Adults

Cannabis and Cannabinoid Research, Journal Year: 2024, Volume and Issue: unknown

Published: April 4, 2024

Background and Aims: Cannabigerol (CBG) is a nonintoxicating cannabinoid synthesized in the Cannabis sativa plant that incorporated into dietary supplements. This study investigated influence of fat an emulsified delivery vehicle on CBG pharmacokinetics (PKs) after oral ingestion by adults.

Language: Английский

---

Cannabidiol (CBD) Products: Use Patterns and Perceptions Within a Sample of Anxious Users

Substance Use & Misuse, Journal Year: 2024, Volume and Issue: 59(11), P. 1604 - 1612

Published: June 30, 2024

Introduction Cannabidiol (CBD) shows promise for a variety of indications, including anxiety. Prior survey work indicates anxiety ranks as top reason which people use cannabidiol (CBD), but no has evaluated individuals using CBD specifically

Language: Английский

---

An Examination of the Anti-Cancer Properties of Plant Cannabinoids in Preclinical Models of Mesothelioma

Cancers, Journal Year: 2022, Volume and Issue: 14(15), P. 3813 - 3813

Published: Aug. 5, 2022

Mesothelioma is an aggressive cancer with limited treatment options and a poor prognosis. Phytocannabinoids possess anti-tumour palliative properties in multiple cancers, however their effects mesothelioma are unknown. We investigated the anti-cancer potential mechanisms of action for several phytocannabinoids cell lines. A panel 13 inhibited growth human (MSTO H2452) rat (II-45) cells vitro, cannabidiol (CBD) cannabigerol (CBG) were most potent compounds. Treatment CBD or CBG resulted G0/G1 arrest, delayed entry into S phase induced apoptosis. also significantly reduced migration invasion. These supported by changes expression genes associated cycle, proliferation, movement following treatment. Gene levels CNR1, GPR55, 5HT1A increased However, syngeneic orthotopic model was unable to increase survival. Our data show that cannabinoids have on vitro alternatives drug delivery may be needed enhance vivo.

Language: Английский

---